Merck Sac-TMT Trial Shows Survival Benefit in Cancer
Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...
Merck
Advertisement
Discovery Life Sciences Launches Luminos for Faster EU Oncology Trials
HUNTSVILLE, Ala. and KASSEL, Germany, May 20, 2026 Discovery Life Sciences has launched Luminos® Comprehensive, a next-generation IVDR-compliant clinical...
Scinai Appoints Eilon Elmalem to Lead Yavne CDMO
JERUSALEM, Israel, May 20, 2026 Scinai Immunotherapeutics Ltd. has announced the appointment of Eilon Elmalem as the new Site...
Merck Unveils Major Oncology Advances at ASCO 2026
RAHWAY, N.J., May 12, 2026 Merck announced a major expansion of its oncology research portfolio ahead of the 2026...
Merck Publishes Science Paper on Scalable Oral PCSK9 Inhibitor Manufacturing
RAHWAY, N.J., May 7, 2026 Merck announced the publication of a landmark scientific paper in the journal Science detailing...
Advertisements
Merck Enpatoran Enters Phase 3 Trial for Lupus Treatment
Darmstadt, Germany | April 30, 2026 Merck has announced the first patient dosing in its global Phase 3 ELOWEN...
Merck Partners with Google Cloud for $1B AI Platform
Las Vegas, Nevada, USA – April 22, 2026 In a landmark move shaping the future of digital transformation in...
Merck FDA Approval of IDVYNSO HIV Treatment Drug
Rahway, New Jersey, USA – April 21, 2026 In a major breakthrough for HIV therapeutics, Merck has received U.S....
Merck ENFLONSIA Approved in EU for Infant RSV Protection
RAHWAY, N.J., April 17, 2026 Merck & Co., Inc. announced that the European Commission (EC) has approved ENFLONSIA™ (clesrovimab),...
Daiichi Sankyo Secures FDA Priority Review for ADC Therapy
Tokyo, Japan & Basking Ridge, New Jersey | April 13, 2026 Daiichi Sankyo, in collaboration with Merck & Co.,...
Advertisement
